Skip to main content
Retour
Watch Compare

Lantern Pharma Inc.

Qualité des données : 83%
LTRN
Nasdaq Manufacturing Chemicals
1,97 €
▲ 0,10 € (5,35%)
Cap. Boursière: 21,38 M
Prix
1,90 €
Cap. Boursière
21,38 M
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—

Quick Summary

Points Clés

Negative free cash flow of -15,68 M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-154,86%
En dessous de la moyenne du secteur (-53,34%)
ROIC-128,40%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio3,33
Interest CoverageN/A

Valorisation

PE (TTM)
-1,25
Au-dessus de la moyenne du secteur (-1,47)
P/B Ratio2,23
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -1,3 -1,5
P/B 2,2 1,6
ROE % -154,9 -53,3
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

ETFs Holding This Stock

MEDX logo MEDX Horizon Kinetics Medical ETF
0,70% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -17,12 M
ROE -154,86% ROA -110,28%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -15,68 M
ROIC -128,40% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 3,33
Interest Coverage N/A Asset Turnover N/A
Working Capital 9,42 M Tangible Book Value 9,59 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1,25 Forward P/E N/A
P/B Ratio 2,23 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -73,32%
Market Cap 21,38 M Enterprise Value 12,99 M
Per Share
EPS (Diluted TTM) -1,57 Revenue / Share N/A
FCF / Share -1,39 OCF / Share -1,39
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 91,58%
SBC-Adj. FCF -16,31 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -17,12 M -20,78 M -15,96 M -14,26 M -12,36 M
EPS (Diluted) -1,57 -1,93 -1,47 — —
Gross Profit — — — — —
Operating Income -17,98 M -22,22 M -17,88 M -14,43 M —
EBITDA — — — — —
R&D Expenses 11,51 M 16,13 M 11,89 M 8,60 M 7,57 M
SG&A Expenses — — — — —
D&A 17 280,0 17 282,0 14 615,0 10 081,0 6 761,0
Interest Expense — — — — —
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 11,04 M 25,57 M 43,65 M 58,84 M 73,95 M
Total Liabilities 4,50 M 4,38 M 2,74 M 2,80 M 2,38 M
Shareholders' Equity 6,53 M 21,19 M 40,91 M 56,04 M 71,57 M
Total Debt — — — — —
Cash & Equivalents 4,42 M 7,51 M 21,94 M 37,20 M 51,52 M
Current Assets 10,80 M 25,25 M 43,34 M 58,72 M 72,72 M
Current Liabilities 4,50 M 4,33 M 2,68 M 2,80 M 2,33 M